TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01825447

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride for injection x 1 dose administered intravenously (IV) push over 4 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone + Naltrexone
Description: Oxycodone hydrochloride (HCl) 20 mg IV and naltrexone HCl 2.4 mg IV administered simultaneously x 1 dose IV push over 4 min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Oxycodone HCl 20 mg for injection x 1 dose IV push over 4 min.
Study: NCT01215981

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: One dose of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Two doses of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B
Study: NCT03067753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monosialoganglioside Ganglioside
Description: Monosialoganglioside ganglioside was given at 100 mg/time, once a day for 2 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone (Steroid Hormone)
Description: Pulse steroid, methylprednisolone, was administered by intravenous infusion over 3 consecutive days. Three grams of methylprednisolone was given in each cycle. Administration of 1 g was infused over 1 h daily for 3 days on an in-patient basis, which then tailed off in 10 days with administration of oral prednisolone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Study: NCT02486445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 15 mg every 12 hours until the completion of the diagnostic work-up, which should not exceed 24 hours (maximum 2 tablets)
Study: NCT03325426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit
Description: Daily use of physical activity tracker coupled with biweekly provider telemonitoring and feedback for 6 months and then additionally without feedback for an additional 6 months
Study: NCT01633645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Velcade

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-days treatment cycle for a maximum of 8 cycles
Study: NCT00110305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-nucleoside reverse transcriptase inhibitor (NRTIs)
Description: Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-nucleoside reverse transcriptase inhibitor (NRTIs)
Description: Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-nucleoside reverse transcriptase inhibitor (NRTIs)
Description: Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
Study: NCT00961532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDAVP injection (desmopressin acetate)
Description: 0.4 mcg/kg in 250 mL NS intravenously once over 30 minutes
Study: NCT00337389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5- Fluorouracil (5-FU)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5- Fluorouracil (5-FU)
Study: NCT04376411

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow-cytometric assay
Description: 100 µl of blood sample was incubated for 20 minutes at 4 C in the dark. Following incubation, red blood cells lysis, washing and analysis a specific software.Forward and side scatter histogram was used to define the lymphocytes population.

Intervention type: DIAGNOSTIC_TEST
Intervention: 2D Echocardiographic analysis
Description: Trans thoracic echocardiographic examination was performed through (PHILIPS -33) echocardiography device with broadband S5-1 transducer

Intervention type: DIAGNOSTIC_TEST
Intervention: Two-Dimensional speckle tracking echocardiography
Description: Two-Dimensional speckle tracking echocardiography was performed on grey scale images of the left ventricle. For offline analysis digital storage software (Qlab 10.4) was used. The frame rate was adjusted to be 60-90 frame/second.
Study: NCT04187521

Intervention type: OTHER
Group type: OTHER
Intervention: Meal B
Description: A breakfast meal with a specific macronutrient proportions.

Intervention type: OTHER
Group type: OTHER
Intervention: Meal B
Description: A breakfast meal with a specific macronutrient proportions.
Study: NCT00337389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab (Avastin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab (Avastin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CoFactor (ANX-510)
Study: NCT05087888

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Undergo functional MRI

Intervention type: PROCEDURE
Intervention: Multiparametric Magnetic Resonance Imaging
Description: Undergo multiparametric MRI

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT00296335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin, doxifluridine and cisplatin
Description: Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin and doxifluridine
Description: Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28-day 84)
Study: NCT01537588

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autograft STG harvest from ACL-deficient leg
Description: Semitendinosus-gracilis graft harvest is undertaken on same limb that is undergoing ACL reconstruction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autograft harvest contralateral to ACL-deficient leg
Description: Semitendinosus-gracilis graft harvest is undertaken on limb contralateral to that undergoing ACL reconstruction
Study: NCT03934801

Intervention type: OTHER
Intervention: Brainstorming 1
Description: Expert recommendation statements will be collected for peer evaluation.

Intervention type: OTHER
Intervention: Ranking Round 1
Description: Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.

Intervention type: OTHER
Intervention: Ranking Round 2
Description: Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.

Intervention type: OTHER
Intervention: Ranking Round 3
Description: Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
Study: NCT04568200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500mg i.v. day 1-22-43-64

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 23 x 1.8 Gy
Description: Radiotherapy 23 x 1.8 Gy

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy 23 x 1.8 Gy
Description: Radiotherapy 23 x 1.8 Gy
Study: NCT04951960

Intervention type: OTHER
Group type: OTHER
Intervention: Higher PEEP setting
Description: PEEP levels are determined according to the higher PEEP-FiO2 tables set plateau pressure less than 30 cmH2O. The duration of measurement at each PEEP levels is 1 hour.

Intervention type: OTHER
Group type: OTHER
Intervention: Higher PEEP setting
Description: PEEP levels are determined according to the higher PEEP-FiO2 tables set plateau pressure less than 30 cmH2O. The duration of measurement at each PEEP levels is 1 hour.

Intervention type: OTHER
Group type: OTHER
Intervention: Lower PEEP setting
Description: PEEP levels are determined according to the lower PEEP-FiO2 tables set plateau pressure less than 30 cmH2O. The duration of measurement at each PEEP levels is 1 hour.

Intervention type: OTHER
Group type: OTHER
Intervention: Lower PEEP setting
Description: PEEP levels are determined according to the lower PEEP-FiO2 tables set plateau pressure less than 30 cmH2O. The duration of measurement at each PEEP levels is 1 hour.
Study: NCT04796467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-617
Description: Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-PSMA-617. Tracer doses of 68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-P16-093
Description: Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-P16-093. Tracer doses of 68Ga-P16-093 will be used to image lesions of prostate cancer by PET/CT.
Study: NCT05322785

Intervention type: OTHER
Group type: OTHER
Intervention: Breath collection
Description: Exhaled breath will be passively collected from subjects during quiet oral breathing through a simple mouthpiece or mask
Study: NCT05958693

Intervention type: DRUG
Intervention: Primaquine
Description: For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
Study: NCT01603524

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OMSC Group
Description: The OMSC Group will receive a multi-component intervention which includes:~1. Coaching and Outreach Facilitation Visits: Each practice will receive on-site support to implement the intervention components.~2. Practice tools and real time prompts: Practices will be provided with 4 tools to support the integration of evidence-based cessation practices into brief clinical encounters as part of a practice-level strategy.~3. Provider Training in Smoking Cessation Interventions: All clinic providers will be invited to a 3 hour training workshop on smoking cessation(CME).~4. Telephone follow-up support program: Clinics will be able to refer smokers embarking upon a quit attempt to the smoker's telephone follow-up counseling program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OMSC + Performance Feedback Group
Description: The OMSC + Performance Feedback Group will receive the same intervention program as the OMSC group. In addition, clinicians will complete a one-hour audit and feedback session prior to the implementation of the OMSC program at their clinic. The goal of the audit and feedback is to increase provider self-efficacy in the delivery of smoking cessation interventions, raise awareness of the current delivery of evidence-based cessation practices, identify areas for improvement, and motivate providers to deliver evidence-based treatments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OMSC + Performance Feedback Group
Description: The OMSC + Performance Feedback Group will receive the same intervention program as the OMSC group. In addition, clinicians will complete a one-hour audit and feedback session prior to the implementation of the OMSC program at their clinic. The goal of the audit and feedback is to increase provider self-efficacy in the delivery of smoking cessation interventions, raise awareness of the current delivery of evidence-based cessation practices, identify areas for improvement, and motivate providers to deliver evidence-based treatments.
Study: NCT03737071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Carbohydrate Diet
Description: Ketogenic dietary intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Simple Calorie Restriction Diet
Description: Simple calorie restriction dietary intervention
Study: NCT03766282

Intervention type: DEVICE
Intervention: ECMO
Description: Extracorporeal membrane oxygenation (ECMO) temporarily supports patients with severe cardio-respiratory failure

Intervention type: DEVICE
Intervention: ECMO
Description: Extracorporeal membrane oxygenation (ECMO) temporarily supports patients with severe cardio-respiratory failure
Study: NCT02176720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDOPA PET
Description: \[18F\]FDOPA radiopharmaceutical will be intravenousely injected for PET-CT scanning of the brain.
Study: NCT01908881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Workshop
Description: The intervention consists in a group workshop (for up to 7 dyads with children aged between 6 and 12 months and two health care professional monitors) of four sessions of two hours each, held weekly. One of the sessions is characterized as including the fathers or other caregivers relevant to the upbringing of the children. Each session is structured around various activities that specifically deal with the skills associated with parental sensitivity and address relevant issues to child rearing, considering the development of the child.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: According to the screening carried out various interventions are offered by Primary Health Care centers (eg. home visits) in the Chile Crece Contigo Program. During pregnancy, if the mother is screened for positive psychosocial risk she would receive different interventions consisting in (usual care at Primary Health Care Centers): home visits, evaluation by social worker and planning interventions according to a multidisciplinary team.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: According to the screening carried out various interventions are offered by Primary Health Care centers (eg. home visits) in the Chile Crece Contigo Program. During pregnancy, if the mother is screened for positive psychosocial risk she would receive different interventions consisting in (usual care at Primary Health Care Centers): home visits, evaluation by social worker and planning interventions according to a multidisciplinary team.
Study: NCT04600011

Intervention type: OTHER
Group type: OTHER
Intervention: Physical and occupational therapy (PT/OT)
Description: Neurologic-specialized and -certified physical and occupational therapists will provide each participant with an initial in-person PT/OT evaluation/treatment session with oversight from a Movement Disorders Neurologist, followed by 4 virtual home visits with tele-PT/OT and care partner supervision every 2 weeks, and culminating with a final in-person evaluation, all with a focus on personalized training in core areas contributing to a patient's individual fall risk, much like in-person visits. Virtual home safety surveillance with the mobile virtual platform is an additional feature of this intervention that aims to optimize the home environment to reduce external factors contributing to fall risk.

Intervention type: OTHER
Group type: OTHER
Intervention: Home Safety Evaluation (HSE)
Description: The VIRTUAL HOME SAFETY EVALUTIONS (HSE)-ONLY ARM where participants ONLY receive the virtual home safety evaluations and surveillance that are built into the original protocol of three of the four tele-OT visits that is being used in Arm 1. The study duration for Arm 2 is about 6 weeks of the primary intervention as described with 3-month and 6-month follow-up calls. The mobile virtual platform for Arm 2 is comprised of a tablet OR smartphone that will be guided through the home by the care partner only and not the patient.
Study: NCT02362568

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Ultrasound cervical exploration
Description: The cervical ultrasound exploration will consist in the ultrasound measurement of the length between the hyoid bone and the skin and the length between the thyroid cartilage and the skin. The ultrasound cervical exploration will be performed in all patients admitted in the postoperative room after a planned surgery performed under general anesthesia.
Study: NCT02969018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Study: NCT01343901

Intervention type: DRUG
Intervention: Bevacizumab
Description: Participants with mCRC and having exclusively liver or liver and lung metastases who were receiving bevacizumab as part of first line treatment for potentially resectable liver metastases as per treating physician's discretion will be observed. All concomitant medications as used in routine clinical practice are allowed.
Study: NCT01181401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPF induction chemotherapy
Description: Docetaxel 75 mg/m2 d 1 Cis-platinum 75 mg/m2 d 1 5-FU 750 mg/m2/d c.i. d 1-4 Cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPF experimental
Description: Docetaxel 40 mg/m2 d 1+8 Cis-platinum 40 mg/m2 d 1+8 5-FU 1500 mg/m2/24h c.i. d 1+8 every 21 day for 3 cycles 2. Antibody therapy with: cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Radiochemotherapy (HART)
Description: Hyperfractionated accelerated radiotherapy with concurrent Cisplatin and 5-Fluorouracil chemotherapy
Study: NCT03945175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYDAYIS
Description: MYDAYIS treatment will be given at a minimum dose of 12.5mg/day and will increase in increments of 12.5mg, up to 37.5mg, based upon clinical response and tolerability.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: During the two-week, placebo lead-in, all patients will receive 12.5mg of placebo at Visit 1 and Visit 2.
Study: NCT01718912

Intervention type: DRUG
Group type: OTHER
Intervention: metronidazole-nystatin oral rinse
Study: NCT01081548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: 20 mg
Study: NCT00572221

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Continuing Quality Improvement and Quality Assurance system
Description: The main intervention is a facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CQI and QA System with Best-Practice Care Protocols
Description: A facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. Research clinical staff will also provide best-practice care protocols designed by our research team to address targeted problem conditions.
Study: NCT01043042

Intervention type: OTHER
Intervention: No interventions will be used in this study
Description: No interventions will be used in this study
Study: NCT02758405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.125% Bupivacaine plus fentanyl 2mcg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.125% Bupivacaine plus fentanyl 2mcg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.125% Bupivacaine plus fentanyl 2mcg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.125% Bupivacaine plus fentanyl 2mcg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 0.125% Bupivacaine plus fentanyl 2mcg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 0.125% Bupivacaine plus fentanyl 2mcg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 0.125% Bupivacaine plus fentanyl 2mcg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 0.125% Bupivacaine plus fentanyl 2mcg/ml

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infusion pump
Description: Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infusion pump
Description: Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infusion pump
Description: Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infusion pump
Description: Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
Study: NCT04104269

Intervention type: DIAGNOSTIC_TEST
Intervention: Heart rupture
Description: Free wall rupture and Ventricular septal rupture
Study: NCT00865488

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADHEXIL
Description: Adhesions prevention
Study: NCT04128787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG881 Formulation 1
Description: AG881 uncoated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG881 Formulation 1
Description: AG881 uncoated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG881 Formulation 1
Description: AG881 uncoated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG881 Formulation 2
Description: AG881 film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG881 Formulation 2
Description: AG881 film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG881 Formulation 2
Description: AG881 film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole capsules
Study: NCT00739271

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early feeding

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: late feeding after bowel sounds return
Description: Traditional method
Study: NCT04363216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Ascor® ascorbic acid 2-hour infusion daily (for 6 days), escalating dose (0.3g/kg, 0.6g/kg, 0.9g/kg).